FDA GRANTS IND APPROVAL FOR PHASE 2 CLINICAL TRI

FDA GRANTS IND APPROVAL FOR PHASE 2 CLINICAL TRIAL OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR TREATING COVID-19
Dec 21, 2020

IPIX future:

Next we should hear that the trial sights have been selected, followed by, Brilacidin shipped, then, Brilacidin arrival at test sights, then we go into a quiet period and watch to see if the stock volume begins to pick up driving up share price, in about 5 or 6 days, after seeing the miracoluious patient recovery with Brilacidin after treatment, thats when lab workers, scientist and others begin buying laarge volumes of IPIX. (Well one can dream)

After 5 or 6 weeks we experience an explosion heard around the world, Brilacidin is announced as a COVID19 KILLER, Coronavirus therapeutic and cure, creating a totally different kind of "free standing" Pharmaceutical Co. Innovation Pharmaceuticals. Leo's Dream comes true, along with all of the shareholders, who have HAD THE GOOD FORTUNE to buy and hold shares of IPIX.

MERRY CHRISTMAS EVERYONE AND HAPPY HOLLIDAYS